Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.11 USD | +2.00% | -2.29% | +21.09% |
May. 31 | Vanda Pharmaceuticals to Commercialize Treatment of Multiple Sclerosis in the US | MT |
May. 27 | Global markets live: UBS, Tesla, Nvidia, Apple, Micron... |
Financials (USD)
Sales 2024 * | 194M | Sales 2025 * | 232M | Capitalization | 297M |
---|---|---|---|---|---|
Net income 2024 * | -3M | Net income 2025 * | -19M | EV / Sales 2024 * | 0.56 x |
Net cash position 2024 * | 189M | Net Debt 2025 * | 65.1M | EV / Sales 2025 * | 1.56 x |
P/E ratio 2024 * |
-85.2
x | P/E ratio 2025 * |
-15.5
x | Employees | 203 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.83% |
Latest transcript on Vanda Pharmaceuticals Inc.
1 day | +2.00% | ||
1 week | -2.29% | ||
1 month | +7.35% | ||
3 months | +14.32% | ||
6 months | +37.37% | ||
Current year | +21.09% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 64 | 02-10-31 | |
Kevin Moran
DFI | Director of Finance/CFO | 40 | 12-11-30 |
Scott Howell
HRO | Human Resources Officer | - | 19-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Dugan
BRD | Director/Board Member | 82 | 05-11-30 |
Chief Executive Officer | 64 | 02-10-31 | |
Stephen Mitchell
BRD | Director/Board Member | 72 | 20-02-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.34% | 28 M€ | -1.00% | ||
0.22% | 25 M€ | -2.35% | - | |
0.05% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 5.11 | +2.00% | 763,512 |
24-05-30 | 5.01 | +1.83% | 446,052 |
24-05-29 | 4.92 | -1.20% | 687,618 |
24-05-28 | 4.98 | -4.78% | 1,078,571 |
24-05-24 | 5.23 | +6.52% | 896,861 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.09% | 297M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- VNDA Stock